COVINGTON

Boston Life Sciences Symposium

THURSDAY, APRIL 30, 2026 | FAIRMONT COPLEY PLAZA, BOSTON



Time Slot	Session	Description
9:00 a.m. – 9:30 a.m.	*Registration and Breakfast*	
9:30 a.m. – 9:35 a.m.	*Opening Remarks* **Megan Gates,** Partner, Covington	
9:35 a.m. – 10:25 a.m.	**Plenary Session One:** *Navigating the Trump 2.0 FDA in Year Two* ▪ **Denise Esposito**, Moderator, Partner, Covington ▪ **Krista Carver**, Partner, Covington ▪ **Joe Franklin**, Chief Legal & Policy Officer, BIO ▪ **Megan Keane**, Partner, Covington ▪ **Rakel Meir,** Senior Vice President, Chief Research Development & Operations Counsel, Biogen	This panel discussion will provide an in-depth analysis of the state of affairs at FDA during the second year of the Trump Administration and its impact on business planning. The session will examine policy developments on topics such as drug pricing, biosimilars, priority vouchers, vaccines, legislative activity, and other hot topics.
10:25 a.m. – 10:45 a.m.	*Morning Break*	
10:45 a.m. – 11:35 a.m.	**Plenary Session Two:** *Corporate Deal Trends – Inside the Changing Landscape* ▪ **Megan Gates**, Moderator, Partner, Covington ▪ **Tim Boarini,** Assistant General Counsel, Head of Transactions, Eli Lilly. ▪ **Andrea DiFabio**, Chief Legal Officer, Xenon Pharmaceuticals, Inc. ▪ **John Hurvitz**, Partner, Covington ▪ **Sean Pitt**, Senior Managing Director, Biopharma, Leerink Partners	This panel will feature perspectives from industry, legal, and financial leaders on prevailing transaction trends, emerging opportunities, and the broader market outlook within the Life Sciences sector. Discussion topics will include developments in deal structures, conditions in the biotech IPO market, alternative financing mechanisms, market shifts in cross-border transactions, including with China-based companies, notable therapeutic areas, evolving technologies and modalities, the implications of the administration's second year, and additional trends expected to shape the year ahead.
11:40 a.m. – 12:00 p.m.	**Cov Talk Session:** *Antitrust in the Life Sciences – The New Enforcement Reality* ▪ **Henry Liu**, Partner, Covington	This tutorial will explore recent developments under the Trump Administration relevant for life sciences companies, including leadership changes, compliance priorities, and best practices for completing deals in the current environment.
12:00 p.m. – 12:40 p.m.	*Buffet Luncheon*	

COVINGTON

Boston Life Sciences Symposium

THURSDAY, APRIL 30, 2026 | FAIRMONT COPLEY PLAZA, BOSTON

Time Slot	Session	Description
12:40 p.m. – 1:25 p.m.	**Luncheon Keynote:** *Resolving the paradox: Why America loves biomedical innovation but resents the companies that deliver it* Featuring **Peter Kolchinsky, PhD** – Founder and Managing Partner of RA Capital Management	In his keynote presentation, Peter Kolchinsky will examine the roots of the biopharma industry's dismal reputation and why attempts to rehabilitate it have failed, and explore a new approach to communicating biopharma's value proposition: Creating entertaining, compelling, educational storytelling to move the cultural conversation in a direction that makes sustainable innovation policy possible.
1:25 p.m. – 1:40 p.m.	*Afternoon Break*	
1:40 p.m. – 2:25 p.m.	**Keynote Speaker:** *Biopharma Regulation at a Crossroads: Perspectives from **Janet Woodcock, M.D.*** Former Acting FDA Commissioner, FDA Principal Deputy Commissioner, and Director of FDA's Center for Drug Evaluation and Research ▪ Moderated by **Michael Labson**, Partner, Covington	In this keynote conversation, Dr. Janet Woodcock will draw on her decades of experience in leadership at FDA to provide insights on the current U.S. drug regulatory landscape and where it is headed. The discussion will explore which recent FDA changes are most meaningful and likely to endure, and where might we see reforms in the U.S. or globally as regulators seek to foster continued innovation while safeguarding the public health.
2:30 p.m. – 3:20 p.m.	**Plenary Session Three:** *New Paradigms for Drug Pricing* ▪ **Kristie Gurley**, Moderator, Partner, Covington ▪ **Grant Castle**, Partner, Covington ▪ **Arun Venkataraman**, Partner, Covington ▪ **Victoria Corke**, Of Counsel, Covington ▪ **TJ Garrigan**, Senior Advisor, Covington	This panel will discuss the dynamic state-of-play for U.S. drug pricing, including updates on the Trump Administration's "most-favored-nation" drug pricing initiative, Inflation Reduction Act "negotiations," and other updates. We'll forecast what's to come with the Administration's rulemaking and ongoing litigation efforts, and discuss general business strategy and risk mitigation trends we are seeing across our client base.
3:25 p.m. – 3:30 p.m.	*Closing Remarks* **Megan Gates,** Partner, Covington	
3:30 p.m. – 4:30 p.m.	*Afternoon Reception*	